Dasatinib as the salvage therapy for chronic myeloid leukemia with blast crisis and central nervous system involvement: A case report

BCR-ABL tyrosine-kinase inhibitors are the first-line therapy for the majority of patients with chronic myelogenous leukemia (CML). Up to 20% of patients who have imatinib-treated CML in blast crisis (BC) experience a relapse in the central nervous system (CNS) due to the poor penetration of the dru...

Descripción completa

Detalles Bibliográficos
Autores principales: LAI, SHIUE-WEI, HUANG, TZU-CHUAN, CHEN, JIA-HONG, WU, YI-YING, CHANG, PING-YING
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2015
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356413/
https://www.ncbi.nlm.nih.gov/pubmed/25789076
http://dx.doi.org/10.3892/ol.2015.2928

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356413/
https://www.ncbi.nlm.nih.gov/pubmed/25789076
http://dx.doi.org/10.3892/ol.2015.2928

Ejemplares similares